Clinical Implications of BRCA Mutations in Advanced Biliary Tract Cancer
Oncology · 2023 · 101 (1) · 41-48
DOI: 10.1159/000527525 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, online erschienen am 18.10.2022. Verfasst von Hyera Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Keimyung University College of Medicine, Daeg…. Hauptthemen laut MEDLINE: Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma. Die Arbeit wurde bisher 9-mal zitiert (Crossref).
Abstract (Originalsprache)
Introduction
Current standard chemotherapy for biliary tract cancer (BTC) has limited survival benefits, and the need for targeted therapies is increasing. This study investigated the genetic profiles and clinical implications of BRCA mutations in patients with advanced BTC.
Methods
Targeted high-throughput sequencing was performed on samples obtained from 25 patients with advanced BTC who had received palliative first-line platinum-based chemotherapy.
Results
Of the 25 patients, 16 (64.0%) were younger than 65 years of age and 16 (64.0%) were male. The BTC cases consisted of intrahepatic cholangiocarcinoma (9, 36.0%), extrahepatic cholangiocarcinoma (5, 20.0%), and gallbladder cancer (11, 44.0%). The median overall survival (OS) and progression-free survival (PFS) of all patients were 11.9 months (95% confidence interval [CI]: 9.2–14.6) and 5.6 months (95% CI: 3.8–7.3), respectively. Genomic alterations in TP53 (52.0%), BRCA (36.0%), ATM (32.0%), ERBB2 (24.0%), NOTCH1 (20.0%), and FGFR3 (20.0%) were frequently reported. TP53 and ATM mutations were associated with OS (TP53: hazard ratio [HR] 2.719, 95% CI: 1.074–6.881, p = 0.035; ATM: HR 2.780, 95% CI: 1.091–7.082, p = 0.032). Patients with BRCA mutations had a slightly improved PFS compared to those with intact BRCA (6.7 months [range, 2.7–10.7 months] vs. 5.3 months [range, 3.6–7.0 months], p = 0.090). However, there was no significant difference in OS between groups (BRCA mutant vs. intact: 10.6 months [range, 3.6–17.6 months] vs. 11.9 months [range, 7.5–16.3 months], p = 0.252). BRCA mutations were significantly associated with PFS in the multivariate analysis (HR 0.150, 95% CI: 0.034–0.655, p = 0.012).
Conclusion
This study demonstrated that BRCA mutations might have a role as predictive biomarkers for palliative first-line platinum-based chemotherapy in patients with advanced BTC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology-Oncology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Keimyung University College of Medicine, Daegu, Republic of Korea, hyerakim9465@gmail.com.
- Division of Hematology-Oncology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Keimyung University College of Medicine, Daegu, Republic of Korea.
Zitieren
APA
Kim, H., Kim, J. Y., & Park, K. U. (2023). Clinical Implications of BRCA Mutations in Advanced Biliary Tract Cancer. Oncology, 101(1), 41-48. https://doi.org/10.1159/000527525
Vancouver
Kim H, Kim JY, Park KU. Clinical Implications of BRCA Mutations in Advanced Biliary Tract Cancer. Oncology. 2023;101(1):41-48. doi:10.1159/000527525
BibTeX
@article{Kim2023,
author = {Kim, Hyera and Kim, Jin Young and Park, Keon Uk},
title = {Clinical Implications of BRCA Mutations in Advanced Biliary Tract Cancer},
journal = {Oncology},
year = {2023},
volume = {101},
number = {1},
pages = {41--48},
doi = {10.1159/000527525}
}
EUVIMED